Latest Peplin news
09-June-09
Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more
28-May-09
Peplin's Positive Phase II AK Trial Results Published in JAAD read more
17-May-09
Positive Results for Peplin's First Phase III AK Trial read more
15-May-09
Peplin Results for the Quarter Ended 31 March 2009 read more
Major shareholders
As of 30 June 2008, Peplin stockholders with 5% or greater
| Name | Listed CDI | |
|---|---|---|
| Number held | Percentage of shares owned | |
| Entities affiliated with MPM BioVentures IV | 42,309,620 | 19.70% |
| Entities affiliated with Acorn Capital Limited | 22,598,120 | 10.90% |
| Entities affiliated with Orbis Global Equity Fund Limited | 27,545,540 | 13.20% |
| Asia Union Investments Pty Limited | 23,568,440 | 11.40% |
Contact us
Medical information
Telephone: +1-800-881-5754
Email: peplin@medcomsol.com
Clinical trial information
Please refer to: www.clinicaltrials.gov for trial information
Corporate information
Email: info@peplin.com
USA
6475 Christie Avenue
Suite 300
Emeryville, California 94608
Telephone: +1-510 653 9700
Facsimile: +1-510 653 9704
AUSTRALIA
Level 2, Brisbane Portal
1 Breakfast Creek Road
Newstead
Brisbane, Queensland 4006
Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299